© 2018 IPFA  |  Sitemap  |  Disclaimer
Design by Stunnenberg

IPFA Members | Focus on HemobrĂ¡s, Brazil

IPFA Member, Hemobrás expands access to public health in Brazil.

The Empresa Brasileira de Hemoderivados e Biotecnologia (Hemobrás), a long-standing member of IPFA, is a public enterprise linked to the Ministry of Health. The company´s intent is to broaden access to public health to all Brazilians through the national production of medicines derivative from blood or attained by genetic engineering. To make its goal possible, Hemobrás is building, in the northeastern part of Brazil, the largest high complex manufacturing plant in Latin America, with the capacity to process 500 thousand liters of plasma every year.

Hemobrás factory will be ready to operate in 2017. However, since September of 2012, an important section of the plant has been serving its purpose housing a cold room at -35 degrees Celsius. That’s where the plasma is received, put under triage and then sent to storage. Parallel to the construction of the factory, Hemobrás progresses with two technology transfer processes: with the French Laboratory of Biotechnologies (LFB), established in 2007, and with Baxter International, since 2012.

The partnership with LFB focuses on the production of blood derivatives.  Understanding the importance of this deal is simple if one takes into consideration the fact that Brazil spends R$ 1 Billion a year importing blood derivatives from other countries.

While the factory is under construction, Hemobrás collects exceeding blood donor’s plasma, stores it at the plant´s cold room and sends it to France. LFB works with the Brazilian plasma and ships it back to Hemobrás as albumin, immunoglobulin, plasmatic factors of coagulation VIII and IX, protrombinic complex and the Von Willebrand factor. In Brazil, these products are distributed within the Brazilian Health Care System - Sistema Único de Saúde (SUS). Once the plant is completed, the exporting of plasma and importing of medications will cease and production will take place on national ground.

The second transfer of technology firmed between Hemobrás and Baxter will last for 10 years and foresees transfer of expertise necessary for the production of recombinant factor VIII, as well as supply of the medication for an equal period of ten years.

The product in question wasn’t offered in Brazil. With the agreement, it has been available since June of 2013. Hemobrás should start producing its own recombinant factor VIII in five years. During 2014, the company will begin distribution of the medication under Hemobrás registry, Hemo-8r. Doing so, institutes Hemobrás as state-of-the-art pharmaceutical industry.

“The national production of blood derivatives and coagulation factor products is extremely important because it reduces Brazil´s vulnerability in the international market. The lack of independency kept Brazil in situation where sometimes there simply was no medicine available due to great imbalance between offer and demand worldwide. Today, only 15 countries house high complexity plants for the production of blood derivatives, and only three of those produce recombinant factor VIII.  Hemobrás and Brazil now belong to this select group and can broaden the population´s access to a quality public healthcare”, says Romulo Maciel Filho, CEO of Hemobrás.

 

 

IPFA Members

 

IPFA Member, Hemobras, Brazil

 

Company Profile Hemobrás 

Hemobrás is a public enterprise linked to the Ministry of Health. The company´s intent is to broaden access to public health to all Brazilians trough the national production of medicines derivative from blood or attained by genetic engineering. To make its goal possible, Hemobrás is building, in the Northeastern part of Brazil, the largest high complex manufacturing plant in Latin America, with the capacity to process 500 thousand liters of plasma/year.

IPFA Member, Hemobras, Brazil

Contact with Hemobrás

Should you have any questions or an interest in the activities of Hemobrás then please contact Mr Osires José Lopez de Melo, Special Advisor to the Hemobrás President and IPFA Executive Board Member

Website Hemobrás

View website Hemobrás